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Abstract
Objectives To determine whether thyroxine
treatment is effective in patients with symptoms of
hypothyroidism but with thyroid function tests within
the reference range, and to investigate the effect of
thyroxine treatment on psychological and physical
wellbeing in healthy participants.
Design Randomised double blind placebo controlled
crossover trial.
Setting Outpatient clinic in a general hospital.
Participants 25 patients with symptoms of
hypothyroidism who had thyroid function tests within
the reference range, and 19 controls.
Methods Participants were given thyroxine 100 ìg or
placebo to take once a day for 12 weeks. Washout
period was six weeks. They were then given the other
to take once a day for 12 weeks. All participants were
assessed physiologically and psychologically at
baseline and on completion of each phase.
Main outcome measures Thyroid function tests,
measures of cognitive function and of psychological
and physical wellbeing.
Results 22 patients and 19 healthy controls
completed the study. At baseline, patients’ scores on 9
out of 15 psychological measures were impaired
when compared with controls. Patients showed a
significantly greater response to placebo than controls
in 3 out of 15 psychological measures. Healthy
participants had significantly lower scores for vitality
when taking thyroxine compared to placebo (mean
(SD) 60 (17) v 73 (16), P < 0.01). However, patients’
scores from psychological tests when taking thyroxine
were no different from those when taking placebo
except for a poorer performance on one visual
reproduction test when taking thyroxine. Serum
concentrations of free thyroxine increased and those
of thyroid stimulating hormone decreased in patients
and controls while they were taking thyroxine,
confirming compliance with treatment. Although
serum concentrations of free triiodothyronine
increased in patients and controls taking thyroxine,
the difference between the response to placebo and to
thyroxine was significant only in the controls.
Conclusions Thyroxine was no more effective than
placebo in improving cognitive function and
psychological wellbeing in patients with symptoms of
hypothyroidism but thyroid function tests within the
reference range. Thyroxine did not improve cognitive
function and psychological wellbeing in healthy
participants.
Introduction
The classic symptoms of hypothyroidism are wide rang›
ing and non›specific, therefore biochemical testing has
become the cornerstone of diagnosis in patients for
whom there is a clinical suspicion of thyroid dysfunction.
However, recent anecdotal evidence has suggested there
may be some clinical benefit in giving thyroxine to
patients with symptoms of hypothyroidism who have
thyroid function tests within the reference range.1–3 After
a series of reports in our local newspaper suggesting that
such patients benefited from thyroxine therapy we
treated two patients empirically with thyroxine, and they
both reported symptomatic relief.4
To investigate this further, we conducted a double
blind placebo controlled crossover trial of thyroxine in
patients who had symptoms of hypothyroidism but
whose thyroid function tests were within the reference
range. A group of controls, who were similar in age and
sex to the patient group, took part in a parallel trial.
The same protocol was used for controls and patients
to test the clinical belief that thyroxine treatment would
have an effect on wellbeing even in participants
without symptoms of hypothyroidism. We assessed
response to thyroxine by using a battery of
biochemical, physical, and psychological tests.
Methods
Participants
Patients were required to have had at least three of the
following symptoms for six months: tiredness, lethargy,
weight gain or inability to lose weight, intolerance to
cold, hair loss, or dry skin or hair. We recruited patients
either by referral from their general practitioner or
hospital clinician, or through an article, published in a
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local newspaper, which described the trial and asked
for volunteers. Controls were healthy volunteers
recruited by personal contact with the investigators. All
participants were required to have no current medical
disorder, no history of thyroid disease, and recent thy›
roid function tests within the reference range.
Because of limited resources, the number of
patients was restricted to the first 25 who met the crite›
ria. Three patients withdrew at an early stage: one was
anxious about the thyroxine dosage, one was ill, and
the third failed to attend for unknown reasons. We did
not enter one interviewed patient into the study
because she was unwilling to have a thyrotrophin
releasing hormone test. Unfortunately, we were unable
to recruit sufficient controls to match the patients
strictly for age and sex. However, the control group was
similar to the patient group (see table A on the BMJ ’s
website). No controls were ineligible and all completed
the study. The local ethical committee approved the
study and we obtained informed consent from all
participants.
Study protocol
The study was a randomised double blind placebo
controlled crossover trial. The two treatment periods of
twelve weeks each were separated by a washout period
of six weeks. Half of the participants were given thyrox›
ine for the first treatment period and placebo for the
second treatment period; half were given placebo first
and thyroxine second. The first 20 participants
received the treatment in 100 ìg capsules; thereafter
100 ìg tablets were supplied. In each case a visually
identical placebo was used. A 14 week supply of tablets,
to be taken once a day, was provided for each phase
and participants were asked to bring the remaining
tablets to their assessment to assess compliance.
Randomisation was by toss of a coin in batches of
four. Controls and patients attended their baseline
assessment simultaneously, which led to unequal
sequence groups. Two of the patients who withdrew
had been assigned to the thyroxine›placebo group. The
code was broken to two investigators (MAP and KMD)
after each participant had completed the trial.
Evaluation
Serum thyroid stimulating hormone, free thyroxine,
free triiodothyronine, cholesterol, and prolactin were
measured at each visit. At baseline, serum ferritin and
antithyroid peroxidase antibodies were measured and
a thyrotrophin releasing hormone test was performed.
Physiological and psychological assessments were per›
formed at baseline and on completion of each phase.
At the end of the trial participants were asked to
identify which treatment they thought they had
received in each phase.
Biochemical measurements
Serum thyroid stimulating hormone, free thyroxine,
cholesterol, and prolactin were analysed at the time the
blood was collected. All blood samples were stored at
–80°C and free triiodothyronine, ferritin, and antithy›
roid peroxidase antibodies were analysed in single
batches to minimise interassay variation. Serum
thyroid stimulating hormone, free thyroxine, free
triiodothyronine, prolactin, and ferritin were measured
by fluorescent microparticle enhanced immunoassay
(Abbott Laboratories Ltd, Maidenhead, UK). An incre›
ment in thyroid stimulating hormone of > 25 mU/l
constituted an abnormal result in the thyrotrophin
releasing hormone test. Antithyroid peroxidase anti›
bodies were measured by a solid phase chemilumines›
cent enzyme immunoassay (DPC, Llanberis, UK).
Cholesterol was measured on a multichannel discrete
analyser (Olympus Diagnostica, Hamburg, Germany)
using a cholesterol oxidase method (Randox Laborato›
ries Ltd, Co. Antrim, UK). Interassay coefficients of
variation were < 15% for thyroid stimulating hor›
mone, < 9% for free thyroxine, < 8.5% for free
triiodothyronine, < 6% for prolactin, and < 2% for
cholesterol.
Physical and psychological evaluation
We recorded supine blood pressure and pulse of
participants using a Criticare (CE1023, Waukesha, WI,
USA) non›invasive blood pressure monitor after they
had rested for five minutes. We measured their weight
on SECA scales (Hamburg, Germany).
We measured cognitive functioning with logical
memory, verbal paired associates, visual reproduction,
and digit span tests from the revised Weschler memory
scale.5 These tests assess attention and concentration,
visual memory, and verbal memory. Psychomotor
speed, attention, and sequencing were assessed by the
trail making test.6
Psychological and physical wellbeing were
measured by using two questionnaires. The hospital
anxiety and depression scale assessed emotional disor›
der7 and the SF›36 health survey measured five health
concepts.8 Two patients failed to complete one page of
Table 1 Response to thyroxine of 22 patients with symptoms of hypothyroidism but
thyroid function tests within the reference range. Values are mean (SD) unless
otherwise stated
Outcome Thyroxine Placebo
Adjusted difference†
(95% CI) P value
Biochemical measures
Thyroid stimulating hormone (mU/l) 0.66 (0.77) 1.77 (1.21) −1.17 (−1.76 to −0.59) <0.001***
Free thyroxine (pmol/l) 17.95 (3.03) 13.68 (3.37) 4.75 (2.67 to 6.83) <0.001***
Free triiodothyronine (pmol/l) 3.72 (0.66) 3.50 (0.54) 0.23 (−0.11 to 0.56) 0.177
Cholesterol (mmol/l) 6.33 (1.17) 6.27 (1.25) 0.05 (−0.27 to 0.37) 0.739
Prolactin (mU/l) 250 (156) 307 (331) −37 (−189 to 116) 0.622
Clinical measures
Pulse (beats/min) 86 (14) 85 (16) −1 (−7 to 6) 0.776
Blood pressure (mm Hg) 83 (12) 80 (12) 1 (−5 to 8) 0.657
Weight (kg) 84 (19) 83 (19) 1 (−1 to 2) 0.389
Cognitive functioning scores
Logical memory I 25 (7) 25 (7) −1 (−3 to 1) 0.231
Logical memory II 22 (8) 21 (7) 0 (−2 to 3) 0.965
Verbal paired associates I 20 (3) 19 (4) 0 (−1 to 2) 0.599
Verbal paired associates II 7 (1) 7 (1) 0 (−1 to 0) 0.671
Visual reproduction I 30 (7) 32 (6) −1.9 (−3.3 to −0.4) 0.016*
Visual reproduction II 27 (8) 27 (8) 1 (−2 to 3) 0.594
Digits forward 10 (1) 9 (2) 1 (0 to 1) 0.133
Digits backward 8 (3) 8 (2) 0 (−1 to 1) 0.985
Trail making test 81 (31) 80 (31) 1 (−9 to 12) 0.779
Psychological functioning scores
Hospital anxiety and depression scale 15 (10) 15 (8) 0 (−4 to 5) 0.874
SF›36 health survey:
Role emotional 48 (47) 64 (44) −18 (−48 to 12) 0.220
Physical functioning 46 (32) 46 (34) 0 (−14 to 14) 0.979
Role physical 36 (41) 43 (40) −8 (−33 to 17) 0.515
General health 42 (24) 48 (24) −6 (−17 to 4) 0.228
Vitality 36 (27) 42 (28) −5 (−24 to 14) 0.571
*P<0.05. ***P<0.001.
†Adjusted by subject and period effects.
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the SF›36 health survey. We calculated the missing
values by taking the means of their scores on their
remaining two visits.
Statistical methods
Baseline characteristics were summarised by means
(SD) or counts and percentages as appropriate. For
each variable, participants were grouped into their
sequence group (thyroxine›placebo or placebo›
thyroxine) to create data summaries in relation to
treatment.
In each set of participants, the effect of treatment
on each variable was studied by using analysis of vari›
ance models in relation to patient, period, and
treatment. The within patient treatment differences
were adjusted by period and 95% confidence limits
created. Some of the results were not normally distrib›
uted; therefore we repeated all analyses using
non›parametric tests and rank data.
The placebo effect was calculated by using
participants who received placebo as their first
treatment. We calculated changes from baseline by
subtracting the baseline value from placebo response.
Results
Baseline measures
All participants had thyroid function results within the
reference range, with the exception of one patient who
had a concentration of thyroid stimulating hormone of
5.8 mU/l (see table A on BMJ ’s website). Concentra›
tions of the hormone in this patient, however, normal›
ised to 4.5 mU/l when taking placebo. Other
biochemical tests for the same patient were within the
reference range. Three participants—the patient
described above, one control, and one patient who
failed to complete the study—had exaggerated
responses to thyrotrophin releasing hormone and
raised concentrations of antithyroid peroxidase anti›
bodies (range 262›1656 U/ml). One patient and one
control had raised concentrations of antithyroid
peroxidase antibodies (211 U/ml and 76 U/ml, respec›
tively) but normal thyrotrophin releasing hormone
responses.
Patients’ scores on psychological testing were signifi›
cantly impaired for logical memory I and II, trail making
test, hospital anxiety and depression scale, and all
components of the SF›36 health survey in comparison
to healthy participants (see table B on BMJ ’s website).
Response to thyroxine or placebo
Biochemical measures
In both groups the serum concentrations of thyroid
stimulating hormone decreased and free thyroxine
increased in response to thyroxine, confirming compli›
ance with treatment. Although free triiodothyronine
concentration increased in both groups when partici›
pants were taking thyroxine, the difference between the
response to placebo and the response to thyroxine was
only significant in the healthy group (tables 1 and 2 ).
This finding was replicated by non›parametric analysis
of the data. The response to thyroxine in patients with
positive autoantibodies or abnormal thyrotrophin
releasing hormone responses did not differ from that
in other participants; numbers were too small for
detailed analysis. No other significant biochemical
changes were observed.
Physical health and psychological measures
We compared the differences in the scores at baseline
and after placebo in participants taking placebo first.
The patients showed a significant symptomatic
improvement in the general health, role physical, and
hospital anxiety and depression scale scores after
placebo, compared with healthy participants (mean
(95% confidence interval) 8 (2 to 15) v − 8 ( − 14 to
− 3), 25 (4 to 46) v − 9 ( − 32 to 13), and − 7 ( − 11 to
− 3) v − 1 ( − 2 to 0), respectively; table 3 ). We observed
no changes in measures of cognitive function. There
was no placebo effect with regard to psychological or
cognitive function scores for the controls (table 3).
In the comparison of the response to thyroxine or
placebo, the only difference in cognitive function tests
was in the patient group, which showed a significant
improvement in visual reproduction I score with
placebo (32 (6) v 30 (7), P = 0.016; table 1). The differ›
ence was less significant on non›parametric analysis
(P = 0.035) and was not replicated in the delayed recall
test, which suggests that the finding may be spurious.
No other tests of cognitive or psychological function
showed differences (table 1). The vitality score for the
healthy control group was significantly better with pla›
cebo compared with thyroxine (73 (16) v 60 (17),
P = 0.007; table 2 ), but otherwise no differences were
observed.
Clinical measures
No significant changes occurred in patients with
respect to blood pressure, pulse rate, or weight during
the study.
Table 2 Response of 19 healthy participants to thyroxine. Values are mean (SD) unless
otherwise stated
Outcome Thyroxine Placebo
Adjusted difference†
(95% CI) P value
Biochemical measures
Thyroid stimulating hormone (mU/l) 0.32 (0.38) 1.55 (1.54) −1.17 (−1.80 to −0.53) 0.001**
Free thyroxine (pmol/l) 20.21 (4.33) 14.29 (5.10) 5.83 (2.02 to 9.63) 0.005**
Free triiodothyronine (pmol/l) 4.39 (1.03) 3.62 (0.52) 0.82 (0.34 to 1.31) 0.002**
Cholesterol (mmol/l) 5.03 (0.84) 5.22 (0.78) −0.21 (−0.46 to 0.04) 0.095
Prolactin (mU/l) 196 (71) 211 (118) −14 (−73 to 46) 0.636
Clinical measures
Pulse (beats/min) 77 (12) 75 (12) 3 (−2 to 8) 0.222
Blood pressure (mm Hg) 74 (9) 72 (11) 3 (−3 to 9) 0.358
Weight (kg) 66 (12) 67 (12) −1 (−1 to 0) 0.240
Cognitive functioning scores
Logical memory I 34 (5) 33 (6) 1 (−1 to 4) 0.380
Logical memory II 31 (7) 31 (6) 1 (−2 to 3) 0.435
Verbal paired associates I 20 (3) 21 (3) −1 (−1 to 0) 0.128
Verbal paired associates II 7 (1) 7 (1) 0 (−1 to 0) 0.413
Visual reproduction I 35 (4) 36 (2) −0.8 (−1.8 to 0.3) 0.148
Visual reproduction II 34 (4) 34 (4) 0 (−1 to 2) 0.723
Digits forward 10 (2) 10 (2) 0 (−1 to 1) 0.605
Digits backward 8 (3) 9 (2) 0 (−1 to 0) 0.338
Trail making test 57 (19) 54 (12) 3 (−3 to 9) 0.368
Psychological functioning scores
Hospital anxiety and depression scale 9 (7) 6 (5) 2 (0 to 5) 0.095
SF›36 health survey:
Role emotional 82 (28) 92 (19) −7 (−21 to 7) 0.318
Physical functioning 91 (14) 93 (10) −1 (−6 to 3) 0.515
Role physical 79 (27) 89 (19) −10 (−26 to 6) 0.216
General health 80 (12) 84 (10) −5 (−11 to 2) 0.135
Vitality 60 (17) 73 (16) −13 (−22 to −4) 0.007**
**P<0.01.
†Adjusted by subject and period effects.
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At the end of the study neither group was able to
identify accurately which treatment period was thyrox›
ine or placebo (table 4).
Discussion
This is the first randomised double blind placebo con›
trolled trial of thyroxine treatment in patients who
have symptoms of hypothyroidism but are biochemi›
cally euthyroid.
Biochemical results
Compliance was confirmed in both groups by the rise
in free thyroxine and fall in thyroid stimulating
hormone while participants were taking thyroxine. The
lack of significant increase in free triiodothyronine in
patients taking thyroxine might reflect impairment of
the peripheral conversion of thyroxine to triiodothyro›
nine. Although this finding requires further investiga›
tion, anecdotal evidence suggests that patients could
benefit from thyroxine treatment alone.9
Comparison of thyroxine and placebo treatments
Psychological testing showed that patients differed
from the controls at baseline. Cognitively, they scored
worse on immediate and delayed verbal recall and had
slower motor movements. They also perceived
themselves to have poorer general health, more
fatigue, increased problems with routine tasks and
activities related to work, and higher levels of anxiety
and depression. These findings may be consistent with
a depressive illness, although no formal assessment
was performed.
Controls showed no significant changes in psycho›
logical measurements after treatment with either
thyroxine or placebo. This suggests that, contrary to
widespread belief, thyroxine does not have a non›
specific effect on wellbeing. In the participants who
received placebo first, patients showed a small but sig›
nificant improvement in general health, physical
wellbeing, and anxiety and depression after placebo
when compared with baseline. Thyroxine treatment,
however, had no greater effect than placebo in this
group of patients. This contrasts with previous studies
in biochemically hypothyroid patients, where thyrox›
ine treatment was associated with psychological
improvement.10–12
Numbers in the study
The small number of participants in this preliminary
study means that, although there was no significant dif›
ference between placebo and thyroxine in 13 of the 14
well validated psychological tests, the power of the
study may not have been sufficient to eliminate defini›
tively a possible biological effect of thyroxine. If this
was the case we would have expected to see a trend in
favour of thyroxine over placebo in the test results,
especially as a recent open intervention study of
thyroxine (mean dose 125 ìg daily) reported self
Table 3 Effect of placebo when given first for patients with symptoms of hypothyroidism but thyroid function tests within the
reference range and controls. Values are mean or mean difference (95% confidence intervals)
Outcome
Patients (n=14) Controls (n=8) Patients v
controls
(P value)Baseline Placebo Placebo−baseline Baseline Placebo Placebo−baseline
Biochemical measures
Thyroid stimulating hormone (mU/l) 1.84 1.78 −0.06 (−0.47 to 0.35) 1.25 1.08 −0.17 (−0.42 to 0.08) 0.685
Free thyroxine (pmol/l) 13.93 14.50 0.50 (−1.75 to 2.75) 14.63 15.25 0.63 (−0.63 to 1.88) 0.932
Free triiodothyronine (pmol/l) 3.20 3.66 0.51 (0.17 to 0.84) 3.55 3.86 0.29 (−0.23 to 0.80) 0.407
Cholesterol (mmol/l) 6.19 6.20 −0.13 (−0.40 to 0.14) 4.99 5.14 0.15 (−0.28 to 0.58) 0.212
Prolactin (mU/l) 286 339 56 (−142 to 254) 240 193 −46 (−94 to 2) 0.419
Clinical measures
Pulse (beats/min) 79 82 5 (−2 to 12) 68 72 5 (−4 to 13) 0.918
Blood pressure (mm Hg) 81 79 −2 (−6 to 1) 77 69 −8 (−18 to 3) 0.175
Weight (kg) 85 85 −1 (−2 to 1) 67 67 0 (−1 to 0) 0.627
Cognitive functioning
Logical memory I 19 26 6 (3 to 9) 28 34 5 (−1 to 12) 0.801
Logical memory II 15 20 5 (2 to 8) 26 31 5 (−2 to 11) 0.777
Verbal paired associates I 16 19 3 (2 to 4) 19 21 2 (0 to 4) 0.211
Verbal paired associates II 7 7 0 (0 to 1) 8 8 0 (−1 to 1) 0.526
Visual reproduction I 32 34 2 (0 to 4) 35 36 1 (−2 to 4) 0.555
Visual reproduction II 28 29 1 (−3 to 5) 33 35 2 (−2 to 7) 0.655
Digits forward 9 9 1 (−1 to 2) 10 10 1 (0 to 1) 0.862
Digits backward 7 8 1 (0 to 2) 10 10 0 (−2 to 1) 0.124
Trail making test 97 82 −16 (−29 to −2) 65 53 −11 (−22 to −1) 0.655
Psychological functioning
Hospital anxiety and depression scale 20 13 −7 (−11 to −3) 8 7 −1 (−2 to 0) 0.034*
SF›36 health survey:
Role emotional 53 71 21 (−4 to 47) 79 80 1 (−17 to 19) 0.240
Physical functioning 42 50 8 (−7 to 23) 98 97 −1 (−2 to 1) 0.354
Role physical 18 45 25 (4 to 46) 97 88 −9 (−32 to 13) 0.031*
General health 40 50 8 (2 to 15) 94 86 −8 (−14 to −3) 0.001**
Vitality 29 47 16 (−4 to 35) 71 71 0 (−7 to 7) 0.214
*P<0.05. **P<0.01.
Table 4 Participants’ ability to distinguish between thyroxine and
placebo at end of trial
Patient group Control group
Correct 9 6
Wrong 10 8
“Don’t know” 3 5
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assessed improvements in energy and poor memory in
80% of 139 participants.9 Our study showed no
discernible trend (table 1).
Conclusion
We can find no support for the hypothesis that people
with symptoms of hypothyroidism but thyroid function
tests within the reference range benefit from treatment
with 100 ìg thyroxine daily. However, our results
require confirmation in a larger study. The improve›
ment noted anecdotally and in open studies may be
due to the placebo effect shown in our study.
We are grateful to the staff of the clinical biochemistry
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analyses and to the staff of the pharmacy department for
performing the randomisation and preparing the capsules. We
thank Goldshield Pharmaceuticals for supplying the placebo
tablets.
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What is already known on this topic
Recent anecdotal accounts suggest that patients
with symptoms of hypothyroidism but who are
biochemically euthyroid may benefit from
thyroxine treatment
No controlled trials in this area have been
reported
What this study adds
This study suggests that thyroxine is no more
effective than placebo in improving psychological
and physical wellbeing in patients who show
symptoms of being clinically hypothyroid but
whose thyroid function tests are within the
reference range
Thyroxine replacement did not improve
psychological and physical wellbeing in healthy
participants
A patient who changed my practice
“That’s very nice, but will it get me pregnant?”
I have to confess, I didn’t understand the question at the time. A
year later, I am starting to. I was an eager new general practitioner
and member of a research team investigating how the internet
might influence patients’ use of primary care, and we had just
begun offering free internet access at our deprived inner city
practice. I had filled the waiting room with posters advertising the
service, and a member of staff was on hand to guide newcomers
through the web. With our new PC and a cup of coffee, we would
help patients empower themselves with the information they’d
been waiting for.
The patient’s recent blood tests for infertility had indicated that
she had polycystic ovary syndrome, and she had come for her
follow up appointment. I explained the likely diagnosis, suggested
she might use our internet service to find more detailed
information, and offered to demonstrate what was available.
Going straight to a website that I knew had some excellent patient
information on the syndrome, I briefly talked her through it and
gave her a printed copy to take away. She and I had always had a
good rapport, I believed. Now she looked disdainfully, first at me
and then at the sheets of paper I offered. “That’s very nice,” she
said, “but will it get me pregnant?”
In my enthusiasm, I had completely misunderstood what the
patient wanted from the consultation. She wanted to conceive
and wasn’t in the least interested in explanations of why she had
failed to thus far—she had come to get a prescription, not
information. However helpful our internet service was intended
to be, she didn’t want that kind of help. Neither, it seems, did
many of our 13 000 patients, only nine of whom used the internet
service in the three months before we closed it. (All but one of the
nine were well educated, had good jobs, and had already used the
internet—not representative of residents of inner city
Manchester.)
Since this rather awkward encounter, I have noticed that many
of my assumptions about what my patients want are equally
mistaken. Very few want information from me. Many don’t even
want a prescription: they want money, or a job, or an escape from
their often appalling lives. I think the internet is a valuable source
of patient information, but I’ve been reminded of a maxim
drummed into me by the first consultant who taught me clinical
medicine: “Assume nothing about your patients—check
everything, every time.”
Our research group is conducting a questionnaire and
interview study to investigate the influence of deprivation on
attitudes to health information and the internet. Meanwhile, I
persist in trying to persuade my patients to expect a little more
from me than housing letters and prescriptions. But I try to
assume less before opening my mouth or offering information.
Robert Varnam general practitioner, Robert Darbishire Practice,
Rusholme Health Centre,Manchester (robert.varnam@man.ac.uk)
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